Literature DB >> 15043023

[Therapy of malignant melanoma at the stage of distant metastasis].

C Garbe1, T K Eigentler.   

Abstract

Treatment of melanoma in the stage of distant metastasis aims on palliation and achievement of durable tumor remission with prolongation of survival. As long as metastasis is confined to one organ system and is removable, surgery remains the treatment of first choice. In limited metastasis radiotherapy may likewise be indicated, particularly in bone and brain metastasis. More extensive metastasis should be treated by chemotherapy or chemoimmunotherapy. Monochemotherapy with dacarbazine, temozolomide, fotemustine and vindesine or its combinations with interferon-alpha are currently preferred. Polychemotherapy or its combinations with interferon-alpha and interleukin-2 are suitable to produce higher response rates but failed to prolong survival. As these treatments are associated with substantially higher toxicity they have been widely abandoned. Combined treatment with dacarbazine and interferon-alpha obtain tumor responses or stable disease in 40-50% and objective tumor remissions in 15-20% of patients. Effective cancer vaccination strategies and blockade of melanoma specific target molecules are currently developed as new treatment options.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15043023     DOI: 10.1007/s00105-003-0684-1

Source DB:  PubMed          Journal:  Hautarzt        ISSN: 0017-8470            Impact factor:   0.751


  50 in total

1.  Survival by radiation therapy oncology group recursive partitioning analysis class and treatment modality in patients with brain metastases from malignant melanoma: a retrospective study.

Authors:  Jeffrey C Buchsbaum; John H Suh; Shih-Yuan Lee; Mark A Chidel; John F Greskovich; Gene H Barnett
Journal:  Cancer       Date:  2002-04-15       Impact factor: 6.860

2.  Prospective randomized trial of the treatment of patients with metastatic melanoma using chemotherapy with cisplatin, dacarbazine, and tamoxifen alone or in combination with interleukin-2 and interferon alfa-2b.

Authors:  S A Rosenberg; J C Yang; D J Schwartzentruber; P Hwu; F M Marincola; S L Topalian; C A Seipp; J H Einhorn; D E White; S M Steinberg
Journal:  J Clin Oncol       Date:  1999-03       Impact factor: 44.544

Review 3.  Cancer immunotherapy with peptide-based vaccines: what have we achieved? Where are we going?

Authors:  Giorgio Parmiani; Chiara Castelli; Piero Dalerba; Roberta Mortarini; Licia Rivoltini; Francesco M Marincola; Andrea Anichini
Journal:  J Natl Cancer Inst       Date:  2002-06-05       Impact factor: 13.506

Review 4.  The role of matrix metalloproteinases in tumor angiogenesis and tumor metastasis.

Authors:  A John; G Tuszynski
Journal:  Pathol Oncol Res       Date:  2001       Impact factor: 3.201

5.  [Locally recurrent and metastatic malignant melanoma. Long-term results and prognostic factors after percutaneous radiotherapy].

Authors:  M H Seegenschmiedt; L Keilholz; A Pieritz; A Altendorf-Hofmann; A Urban; H Schell; W Hohenberger; R Sauer
Journal:  Strahlenther Onkol       Date:  1999-09       Impact factor: 3.621

6.  Combination chemotherapy plus BCG in the treatment of disseminated malignant melanoma: a Southwest Oncology Group Study.

Authors:  J J Costanzi; M Al-Sarraf; C Groppe; R Bottomley; C Fabian; J Neidhart; D Dixon
Journal:  Med Pediatr Oncol       Date:  1982

Review 7.  Palliative therapy of disseminated malignant melanoma: a systematic review of 41 randomised clinical trials.

Authors:  Thomas K Eigentler; Ulrich M Caroli; Peter Radny; Claus Garbe
Journal:  Lancet Oncol       Date:  2003-12       Impact factor: 41.316

8.  Combination chemotherapy and hormonal therapy in the treatment of malignant melanoma.

Authors:  E F McClay; M J Mastrangelo; R E Bellet; D Berd
Journal:  Cancer Treat Rep       Date:  1987-05

9.  DTIC, CCNU, bleomycin and vincristine (BOLD) in metastatic melanoma.

Authors:  H F Seigler; V S Lucas; N J Pickett; A T Huang
Journal:  Cancer       Date:  1980-12-01       Impact factor: 6.860

10.  Randomized trial of recombinant alpha 2b-interferon with or without indomethacin in patients with metastatic malignant melanoma.

Authors:  R L Miller; R G Steis; J W Clark; J W Smith; E Crum; J E McKnight; M J Hawkins; M J Jones; D L Longo; W J Urba
Journal:  Cancer Res       Date:  1989-04-01       Impact factor: 12.701

View more
  6 in total

Review 1.  [Role of MHC class I molecules in anti-tumoral mechanisms in human malignant melanoma].

Authors:  J Dissemond; S Grabbe
Journal:  Hautarzt       Date:  2006-08       Impact factor: 0.751

Review 2.  [Therapy of malignant melanoma. First-, second- and pathogenesis-oriented third-line therapies].

Authors:  K Rass; D Tadler; W Tilgen
Journal:  Hautarzt       Date:  2006-09       Impact factor: 0.751

3.  [Malignant melanoma masquerading as a neurotrophic ulcer].

Authors:  Larissa Schöttler; Andreas Körber; Natalia Denisjuk; Julia Freise; Joachim Dissemond
Journal:  Med Klin (Munich)       Date:  2009-09-23

Review 4.  [Experimental treatment of malignant melanoma and its rationale].

Authors:  K Rass; M Diefenbacher; W Tilgen
Journal:  Hautarzt       Date:  2008-06       Impact factor: 0.751

5.  Low expression of CD161 and NKG2D activating NK receptor is associated with impaired NK cell cytotoxicity in metastatic melanoma patients.

Authors:  Gordana Konjević; Katarina Mirjacić Martinović; Ana Vuletić; Viktor Jović; Vladimir Jurisić; Nada Babović; Ivan Spuzić
Journal:  Clin Exp Metastasis       Date:  2007-02-13       Impact factor: 4.510

6.  Systemic therapy of non-resectable metastatic melanoma.

Authors:  Azadeh Orouji; Sergij Goerdt; Jochen Utikal
Journal:  Cancers (Basel)       Date:  2010-05-26       Impact factor: 6.639

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.